Non-HDL-C

More documents

Recommendations

Info

Time to move beyond LDL
Should both <strong>HDL</strong>-C and LDL- C be targets for lipid therapy
Page 1 and 2: Current Targets and Treatment Gaps
Page 3 and 4: Fasting and Nonfasting TG: Equally
Page 5 and 6: Role of Low HDL-C in Residual Cardi
Page 7 and 8: Association Between LDL-C, Non-HDL-
Page 9 and 10: CHD risk predicted by HDL and LDL i
Page 11 and 12: New CV events in MI patients with n
Page 13 and 14: Percentage of patients reaching ADA
Page 15 and 16: IS THERE AN ASYMPTOTIC LIMIT FOR LD
Page 17: CAD risk can be reduced to a maximu
Page 21: Should HDL Raising Be a Target for
Page 28 and 29: Recommendations for management of d
Page 30: NCEP ATPIII, AHA, and ADA: Recommen
Page 33 and 34: NCEP ATP III Guidelines (Cont.) If
Page 35 and 36: American Diabetes Association Stand
Page 37 and 38: Target Levels Risk Level Initiate t
Page 44 and 45: Conclusion Non pharmacological stra

Non-HDL-C

Create successful ePaper yourself

Delete template?

Save as template?